Evidence boundary: This article reviews published, patent, analytical, and regulatory sources involving the specific molecular forms identified below. Findings involving albumin-binding CJC-1295 with Drug Affinity Complex (DAC), other GHRH analogues, or any separately manufactured material cannot be transferred automatically to CJC-1295 without DAC. Nothing here is a claim about an FDB research product, a recommendation for human use, or medical advice. First Due Biotech products are offered strictly for laboratory research use only and are not for human consumption.
What is CJC-1295 without DAC?
CJC-1295 without DAC is a common name for a synthetic 29-amino-acid analogue of the active N-terminal portion of human growth hormone–releasing hormone (GHRH). The most precise description is [D-Ala²,Gln⁸,Ala¹⁵,Leu²⁷]-hGRF(1-29)-NH₂. The same intended sequence is frequently called Modified GRF (1-29) or Mod GRF 1-29.
Those names are useful, but they carry an important historical complication. In the original ConjuChem development program, the name CJC-1295 referred to a longer, albumin-binding derivative that added a maleimide-bearing lysine to the 29-residue core. The added group—the Drug Affinity Complex, or DAC—was designed to form a covalent bond with circulating albumin and substantially extend exposure.
“CJC-1295 without DAC” is therefore a later label for the unextended core rather than the molecule originally described as CJC-1295 in the best-known human publications. This distinction is not cosmetic. It separates two active moieties with different structures and sharply different disposition profiles.
Why the distinction matters
Many summaries of CJC-1295 combine evidence from the DAC and non-DAC forms. That produces a much stronger-looking evidence record than the exact non-DAC molecule actually has.
The human studies most often cited for prolonged growth hormone and IGF-1 responses investigated the albumin-binding DAC molecule. The study of growth-hormone pulsatility also used that long-acting form. Those findings cannot establish the human pharmacokinetics, endocrine response, benefits, or adverse-event frequency of the shorter non-DAC peptide.
For the exact non-DAC 29-mer, the direct record identified through the evidence cutoff consists mainly of:
- Patent experiments in rat pituitary cells and male rats
- A small rat experiment embedded in an anti-doping analytical-method study
- Forensic identification of a peptide in a seized preparation
- FDA’s chemistry, safety, and effectiveness review
No peer-reviewed human interventional study of the verified non-DAC molecular entity was identified.
That absence is the central evidence fact. It does not mean that the molecule is scientifically uninteresting. It means that its value to a research library lies in correctly defining the molecule, identifying the limited direct signals, and separating them from claims imported from related compounds.
Research at a glance
| Research question | What the identified evidence supports | Evidence assessment |
|---|---|---|
| Molecular identity | FDA, patent, and analytical sources converge on a tetrasubstituted, amidated 29-mer | Moderate to high for the intended sequence; marketplace naming remains unreliable |
| GHRH-pathway activity | Patent experiments reported growth-hormone release in rat pituitary cells and an acute rat study | Preliminary preclinical evidence |
| Disposition | Patent assay did not detect the non-DAC core after 60 minutes in rats; a later analytical method detected intact peptide through eight hours | Conflicting qualitative rat detectability; no validated half-life |
| Human pharmacokinetics | No direct study of the verified non-DAC form was identified | Absent |
| Human GH or IGF-1 response | No direct study of the verified non-DAC form was identified | Absent |
| Body composition, metabolism, sleep, recovery, cognition, or performance | No direct human outcome study was identified | Absent |
| Human safety | No molecule-specific clinical safety dataset was identified | Absent |
| Product identity and quality | FDA documented inconsistent naming and incomplete characterization across sources | Material research concern |
Molecular design and research rationale
The non-DAC peptide is derived from hGRF(1-29)-NH₂, the portion of endogenous GHRH responsible for receptor activation. Four substitutions distinguish it from the native 29-residue sequence:
| Position | Native residue | Substituted residue | Research rationale |
|---|---|---|---|
| 2 | L-alanine | D-alanine | Intended to resist rapid N-terminal enzymatic cleavage |
| 8 | Asparagine | Glutamine | Conservative substitution used in stabilized analogue design |
| 15 | Glycine | Alanine | Substitution used in earlier GHRH analogue programs |
| 27 | Methionine | Leucine | Removes an oxidation-prone methionine residue |
The design is scientifically coherent: retain the receptor-active GHRH fragment while modifying positions associated with instability. Related human research on a D-Ala²-only analogue reported slower disappearance than native hGRF(1-29), supporting the general stabilization rationale. That partial analogue differs at three other positions, however, so its quantitative pharmacokinetic findings cannot be assigned to the full four-substitution molecule.
The expected proximal pathway is GHRH-receptor activation on pituitary somatotrophs, followed by cyclic-AMP signaling and endogenous growth-hormone release. Downstream IGF-1 production is biologically plausible within this pathway. For the exact non-DAC peptide, however, identified sources do not establish human receptor potency, a human GH or IGF-1 dose-response, signaling selectivity, or desensitization behavior.
What the direct preclinical evidence reported
The ConjuChem patent designated the non-DAC core as Example 5. In reported experiments, Example 5 stimulated growth-hormone release from cultured rat anterior pituitary cells and produced an acute growth-hormone response in male rats. These findings support proximal biological activity in rat systems.
The patent also compared the disposition of the core with the albumin-reactive derivative. Under its assay conditions, the non-DAC core disappeared rapidly and was not detected after 60 minutes, while the DAC derivative remained detectable through 96 hours.
That is a useful structural comparison, but it is not a human half-life study. The patent did not report a numerical half-life for the non-DAC core, and patent evidence does not carry the same evidentiary weight as a complete peer-reviewed pharmacology program.
A 2016 analytical-method paper later used the same four-substitution 29-mer in a very small rat experiment. Its mass-spectrometry method detected intact peptide at two, four, and eight hours after administration. The investigators were developing an anti-doping detection method; they did not estimate pharmacokinetic parameters or measure growth hormone, IGF-1, safety, or functional outcomes.
The different detection windows are best treated as an assay and study-design conflict. Differences in analytical sensitivity, matrix, dose, material, or sampling could explain them. Neither experiment establishes the widely repeated claim of an approximately 30-minute human half-life.
What the human CJC-1295 studies actually investigated
Published human studies by Teichman and colleagues and by Ionescu and Frohman are scientifically important—but for the DAC molecule.
In healthy adults, investigators reported prolonged exposure and sustained growth-hormone and IGF-1 changes after the albumin-binding form. A separate frequent-sampling study reported that pulsatile growth-hormone secretion persisted while trough and mean concentrations were elevated one week after the DAC intervention.
Those results demonstrate what albumin-binding CJC-1295 did under those study conditions. They do not show that CJC-1295 without DAC has a multi-day half-life, produces the same endocrine pattern, preserves pulsatility in the same manner, or shares the same safety profile.
The distinction is especially important because DAC was created to change the feature most relevant to those findings: duration of exposure. Removing the albumin-binding group removes the basis for transferring the DAC pharmacokinetic values.
The only identifiable CJC-1295 clinical registry record, NCT00267527, concerned the long-acting development program in HIV-associated visceral obesity. The trial was terminated, and it does not supply clinical evidence for the non-DAC peptide.
What has not been established in humans
No direct human study of the verified non-DAC 29-mer was identified for:
- Absorption, bioavailability, half-life, clearance, or metabolism
- Growth hormone, IGF-1, or IGFBP-3 responses
- Body composition or visceral adipose tissue
- Glucose, insulin, lipid, or broader metabolic outcomes
- Sleep or circadian endpoints
- Tissue repair, recovery, or healing
- Cognition, physical performance, or functional outcomes
- Short- or long-term adverse-event incidence
This means that popular claims in these areas are not merely supported by small or inconsistent trials; for this exact molecule, direct human outcome evidence is absent in the identified record.
That conclusion also applies to combination claims. No controlled human evidence was identified establishing a specific interaction or “synergy” between the non-DAC peptide and ipamorelin or another secretagogue.
Safety: uncertainty is not evidence of safety
The lack of a human adverse-event dataset prevents reliable estimates of frequency or severity. It also makes two opposite errors possible: assuming the molecule is safe because few events have been reported, or presenting class-based hazards as though they were observed event rates for this exact peptide.
FDA’s 2024 review discussed plausible concerns associated with growth-hormone and IGF-1 elevation, including glucose intolerance, fluid retention, intracranial hypertension, endocrine interactions, and neoplasm-related questions. For the non-DAC form, these remain mechanism- and class-based cautions rather than measured clinical incidence.
FDA also emphasized peptide-specific quality questions, including aggregation, peptide-related impurities, immunogenicity, sterility, endotoxin, and particulates. These issues depend not only on the nominal amino-acid sequence but on synthesis, purification, counterion, formulation, storage, and analytical control.
Adverse events reported in studies of the DAC molecule cannot be converted into non-DAC incidence estimates. Equally, the absence of reported adverse events in brief rat and analytical experiments cannot establish safety.
Identity and analytical verification
This evidence base has an unusual problem: the name itself is not dependable enough to define the test article.
FDA documented at least five CJC-1295-related bulk substances and at least nine names used across nominations and public sources. The non-DAC free base and its acetate salt share an active peptide moiety but remain distinct bulk substances. The DAC forms contain a different active moiety. Public database and marketplace synonyms sometimes blur those categories.
As a result, a label reading “CJC-1295,” “no DAC,” or “Modified GRF (1-29)” does not by itself establish:
- The complete amino-acid sequence and stereochemistry
- Presence or absence of the DAC extension
- Free-base or salt form
- Peptide purity and related-sequence impurities
- Aggregation state
- Endotoxin, bioburden, sterility, or particulate characteristics
For research interpretation, molecular identity and lot-specific analytical documentation are therefore part of the evidence—not an administrative detail.
Regulatory and anti-doping context
No FDA-approved drug containing CJC-1295 without DAC was identified. In its 2024 scientific review, FDA proposed that the non-DAC free base, non-DAC acetate, and three DAC-related forms not be added to the Section 503A Bulks List. The Pharmacy Compounding Advisory Committee later voted 0–13 against inclusion of the free base and 1–12 against inclusion of the acetate.
Those votes were advisory and should not be described as a drug-approval decision or, by themselves, as final rulemaking. The FDA record is nevertheless highly relevant because it separately analyzed the non-DAC and DAC forms and found important gaps in identity, characterization, safety, and effectiveness evidence.
The 2026 World Anti-Doping Agency Prohibited List names CJC-1295 among growth-hormone-releasing factors prohibited at all times. The listing does not distinguish DAC from non-DAC forms.
Regulatory status and sports rules can change, so both should be checked again immediately before publication or reliance.
Why the research record remains scientifically useful
CJC-1295 without DAC is a useful case study in how small structural changes can reshape an evidence base. The non-DAC core has a rational stabilized-GHRH design and preliminary rat-system activity. It also illustrates why mechanism, analogue evidence, and exact-molecule evidence must remain separate.
The most constructive research direction is not to inflate the existing record, but to define what a stronger program would require: verified molecular identity; validated quantitative pharmacokinetics; receptor and signaling characterization; controlled human pharmacodynamic research where legally and ethically authorized; systematic safety assessment; and outcome studies that do not rely on DAC or related-analogue substitution.
That leaves a precise, research-positive conclusion: the non-DAC peptide is a distinct GHRH-analogue research target with a plausible design and limited direct preclinical signals, while its human pharmacology, safety, and outcomes remain unestablished.
Key takeaways
- CJC-1295 without DAC commonly refers to
[D-Ala²,Gln⁸,Ala¹⁵,Leu²⁷]-hGRF(1-29)-NH₂, also called Modified GRF (1-29). - Original CJC-1295 publications generally used the albumin-binding DAC molecule, not the unextended 29-mer.
- Patent experiments reported GHRH-pathway activity in rat systems, and an analytical study detected intact peptide in a small rat experiment.
- The available rat studies do not establish a numerical human half-life.
- No peer-reviewed human interventional evidence for the verified non-DAC molecule was identified.
- Human findings for DAC CJC-1295, sermorelin, tesamorelin, or other secretagogues cannot be transferred automatically.
- Naming ambiguity makes exact sequence, form, and lot-specific characterization central to credible research.
- FDA’s 2024 review and advisory-vote record should be described precisely and not confused with drug approval or final rulemaking.